Article PDF
Avoid common mistakes on your manuscript.
References
Zajicek JP, Scolding NJ, Foster O, et al. (1999) Central nervous system sarcoidosis- diagnosis and management. QJM 92:103–117
Barthel HR, Gille T, Halbsguth A, Kramer M (2005) Successful treatment with adalimumab in infliximab-resistant Crohn’s disease. J Gastroenterol Hepatol 20:1464–1465
Ziegenhagen MW, Rothe ME, Zissel G, Muller-Quernheim J (2002) Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 19:164–166
Sollberger M, Fluri F, Baumann T, et al. (2004) Successful treatment of steroidrefractory neurosarcoidosis with infliximab. J Neurol 251:760–761
Doty JD, Mazur JE, Judson MA (2005) Treatment of sarcoidosis with infliximab. Chest 127:1064–1071
Heffernan MP, Smith DI (2006) Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 142:17–19
Ziegenhagen MW, Rothe ME, Zissel G, Muller-Quernheim J (2002) Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 19:164–166
Geborek P, Bladstrom A, Turesson C, et al. (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64:657–658
Gupta G, Gelfand JM, Lewis JD (2005) Increased risk of demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 129:819–826
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marnane, M., Lynch, T., Scott, J. et al. Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab. J Neurol 256, 139–140 (2009). https://doi.org/10.1007/s00415-009-0077-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-009-0077-1